Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2018

View Archived Issues

Arrevus receives NIAID grant to support research using ARV-1502

Japanese authorities grant Sakigake designation to CLBS-12

Sakigake designation awarded to tafamidis meglumine

Novel HBsAg secretion inhibitors synthesized at Novartis

NOTCH and MAPK signaling linked to worse colorectal cancer survival

Preliminary phase I pharmacokinetic data reported for AZD-8186

Mylan to introduce new triple combo once-daily HIV treatment in U.S.

Incyte patents novel MAP4K1 inhibitors

Nabriva Therapeutics and Roivant Sciences enter lefamulin license agreement

New mu-opioid receptor agonists identified at Mebias Discovery

GlaxoSmithKline presents novel viral 3C and 3CL protease inhibitors

The University of Saskatchewan divulges alpha-synuclein aggregation inhibitors

FDA grants orphan drug designation to CYP-001

Edge Therapeutics discontinues phase III NEWTON 2 study of EG-1962

First patient enrolled in phase IIb trial of AmnioFix Injectable for the treatment of OA of the knee

Vifor Pharma grants Zeria license to develop and market Veltassa in Japan

Abide Therapeutics grants Celgene worldwide license for ABX-1772

EMA accepts BioMarin's MAA for pegvaliase to treat adults with PKU

Lanadelumab submissions in E.U. and Canada accepted for review

Urovant initiates phase III trial of vibegron in overactive bladder

Balixafortide/eribulin combination shows antitumor activity in metastatic breast cancer patients

Curadim licenses rights to Ube's LPA1 selective antagonist

MediciNova announces plans to study MN-166 for chemotherapy-induced peripheral neuropathy

pSivida announces acquisition of Icon Bioscience

Kazia Therapeutics initiates phase II trial of GDC-0084

Five Prime initiates phase I study of first-in-class B7-H4 antibody FPA-150

METTL3 linked to hepatocellular carcinogenesis

Prometic Life Sciences offers new data from phase II study of PBI-4050 in Alstrom syndrome

Janssen files for approval of apalutamide in Japan

Takeda considers making offer for Shire

Zeria Pharmaceutical applies for approval of Z-213 in Japan

Redx suspends enrollment in phase I/IIa study of RXC-004

C4X licenses orexin-1 receptor antagonist C4X-3256 to Indivior

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...